Pasithea TherapeuticsKTTA
13F holders, Q4 2025 (December 31)25holders +6
10new positions
5sold out
1famous investor
$1.29avg. 13F price*
At the end of Q4 2025, 25 institutions reported holding Pasithea Therapeutics Corp. (KTTA) in their 13F filings, up 6 from Q3 2025. 10 opened new positions and 5 sold out. The largest holders were Janus Henderson Group PLC ($2.7M), Squadron Capital Management LLC ($2.7M) and Vivo Capital, LLC ($2.7M). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Pasithea Therapeutics Corp.
- CUSIP
- 70261F202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $13.1M |
| Exits | 5 | $63K |
All 13F filers, Q3 2025 → Q4 2025: 10,297,889 shares bought and 117,811 shares sold, net +10,180,078 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 25 holders
| Janus Henderson Group PLC | 0.00% | New | 2,100,000 | $2.7M |
| Squadron Capital Management LLC | 1.21% | — | 2,100,000 | $2.7M |
| Vivo Capital, LLC | 0.18% | New | 2,100,000 | $2.7M |
| Adage Capital Partners Gp, L.L.C. | 0.00% | New | 2,100,000 | $2.7M |
| Ameriprise Financial Inc. | 0.00% | New | 1,930,128 | $2.5M |
| Cable Car Capital, LP | 0.04% | New | 500,000 | $645K |
| Acuta Capital Partners, LLC | 0.39% | New | 450,000 | $581K |
| Stempoint Capital LP | 0.08% | New | 355,082 | $458K |
| AdvisorShares Investments LLC | 0.07% | Add +18.3% | 304,721 | $393K |
| Persistent Asset Partners Ltd | 0.18% | New | 290,555 | $375K |
| Stonepine Capital Management, LLC | 0.28% | New | 275,062 | $355K |
| Vanguard Group Inc. | 0.00% | Add +81.5% | 97,675 | $126K |
| Jane Street Group, LLC | 0.00% | Add +137.0% | 59,372 | $77K |
| Citadel Advisors | 0.00% | Reduce -16.6% | 56,183 | $72K |
| Geode Capital Management, LLC | 0.00% | Add +113.9% | 54,495 | $70K |
| Two Sigma Investments, LP | 0.00% | Add +36.4% | 48,773 | $63K |
| Northern Trust Corp. | 0.00% | New | 28,090 | $36K |
| XTX Topco Ltd | 0.00% | Reduce -39.5% | 20,783 | $27K |
| UBS Group AG | 0.00% | Reduce -27.8% | 13,263 | $17K |
| Hurley Capital, LLC | 0.00% | No change | 3,689 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +142.2% | 2,947 | $4K |
| SBI Securities Co., Ltd. | 0.00% | No change | 1,051 | $1K |
| JPMorgan Chase & Co. | 0.00% | No change | 150 | $194 |
| Bank of America Corp. | 0.00% | Add +8.6% | 63 | $81 |
| Royal Bank of Canada | 0.00% | No change | 250 | $0 |
"% of holder's portfolio" is KTTA's weight in each manager's 13F, not the share of Pasithea Therapeutics Corp. the manager owns.